SRF, serum response factor, 6722

N. diseases: 147; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.220 Biomarker group MGD
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.010 Biomarker disease BEFREE <b>Conclusions:</b> These data indicate that TCF21 antagonizes the MYOCD-SRF pathway through multiple mechanisms, further establishing a role for this CAD associated gene in fundamental SMC processes and indicating the importance of smooth muscle response to vascular stress and phenotypic modulation of this cell type in CAD risk. 31815603 2020
CUI: C3888088
Disease: SMITH-MCCORT DYSPLASIA 1
SMITH-MCCORT DYSPLASIA 1 		0.030 Biomarker disease BEFREE <b>Objective:</b> To better understand how TCF21 affects SMC phenotype, we sought to investigate the possible mechanisms by which it regulates the lineage determining myocardin (MYOCD)-serum response factor (SRF) pathway. 31815603 2020
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma 		0.030 Biomarker disease BEFREE 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. 30951312 2019
CUI: C0011644
Disease: Scleroderma
Scleroderma 		0.010 Biomarker disease BEFREE 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. 30951312 2019
CUI: C0878544
Disease: Cardiomyopathies
Cardiomyopathies 		0.010 AlteredExpression group BEFREE Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. 11247792 2001
CUI: C0231341
Disease: Premature aging syndrome
Premature aging syndrome 		0.010 Biomarker disease BEFREE Premature aging in skeletal muscle lacking serum response factor. 19079548 2008
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.100 AlteredExpression disease BEFREE Megakaryoblastic leukemia 1 (MKL1), identified as part of the t(1;22) translocation specific to acute megakaryoblastic leukemia, is highly expressed in differentiated muscle cells and promotes muscle differentiation by activating serum response factor (SRF). 19136660 2009
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.100 Biomarker disease BEFREE Megakaryoblastic leukemia 1 (MKL1), also known as MAL or myocardin-related transcription factor A (MRTF-A), is a coactivator of serum response factor, which regulates transcription of actin and actin cytoskeleton-related genes. 26224645 2015
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.100 GeneticVariation disease BEFREE Megakaryoblastic leukemia 1 (MKL1) is a coactivator of serum response factor (SRF) that promotes the expression of genes associated with cell proliferation, motility, adhesion, and differentiation-processes that also involve dynamic cytoskeletal changes in the cell. 26554816 2015
CUI: C0023462
Disease: Acute Megakaryocytic Leukemias
Acute Megakaryocytic Leukemias 		0.100 Biomarker disease BEFREE Megakaryoblastic leukemia 1 (MKL1) is a coactivator of serum response factor and together regulate transcription of actin cytoskeleton genes. 31582539 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 AlteredExpression disease BEFREE SRF expression was determined by Western blotting of benign intestinal cells and human colon cancer cell lines. 15313381 2004
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.010 AlteredExpression disease BEFREE SRF expression was determined by Western blotting of benign intestinal cells and human colon cancer cell lines. 15313381 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 AlteredExpression group BEFREE SRF expression correlated with the tumor size of the PTCs (P<0.05). 19513551 2009
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma 		0.010 AlteredExpression disease BEFREE SRF was mainly expressed in cancer cells, showing a strong nuclear and/or cytoplasmic staining in PTC. 19513551 2009
CUI: C0007133
Disease: Carcinoma, Papillary
Carcinoma, Papillary 		0.010 AlteredExpression disease BEFREE SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). 19513551 2009
CUI: C0151468
Disease: Thyroid Gland Follicular Adenoma
Thyroid Gland Follicular Adenoma 		0.010 AlteredExpression disease BEFREE SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). 19513551 2009
CUI: C0205647
Disease: Follicular adenoma
Follicular adenoma 		0.010 AlteredExpression disease BEFREE SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). 19513551 2009
CUI: C0205696
Disease: Anaplastic carcinoma
Anaplastic carcinoma 		0.010 AlteredExpression disease BEFREE SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). 19513551 2009
CUI: C0205698
Disease: Undifferentiated carcinoma
Undifferentiated carcinoma 		0.010 AlteredExpression disease BEFREE SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). 19513551 2009
CUI: C0871388
Disease: social stress
social stress 		0.010 Biomarker disease BEFREE Serum response factor promotes resilience to chronic social stress through the induction of DeltaFosB. 20980616 2010
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.020 Biomarker group BEFREE SRF immunoreactivity in prostate tumor samples was shown for the first time to be associated with castration-resistance. 23359479 2013
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.040 AlteredExpression phenotype BEFREE Serum response factor (SRF) is a transcription factor that plays a central role in carcinogenesis and tumor progression in several types of cancers. 24173109 2014
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.030 Biomarker phenotype BEFREE Serum response factor (SRF) is a transcription factor that plays a central role in carcinogenesis and tumor progression in several types of cancers. 24173109 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.290 Biomarker disease BEFREE SRF-VP16iHep mHCC reveal convergent Ras/MAPK and Rho/actin signaling as a highly oncogenic driver mechanism for hepatocarcinogenesis. 25266280 2015